Next Article in Journal
Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults
Next Article in Special Issue
Importance of ABC Transporters in the Survival of Parasitic Nematodes and the Prospect for the Development of Novel Control Strategies
Previous Article in Journal
Genome Characteristics of Two Ranavirus Isolates from Mandarin Fish and Largemouth Bass
Previous Article in Special Issue
The Brown Alga Bifurcaria bifurcata Presents an Anthelmintic Activity on All Developmental Stages of the Parasitic Nematode Heligmosomoides polygyrus bakeri
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Plasmodium falciparum Chloroquine-pfcrt Resistant Haplotypes in Brazilian Endemic Areas Four Decades after CQ Withdrawn

1
Laboratório de Pesquisa em Malária, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21041-361, Brazil
2
Centro de Pesquisa, Diagnóstico e Treinamento em Malária (CPD-Mal), Reference Laboratory for Malaria in the Extra-Amazonian Region for the Brazilian Ministry of Health, Secretaria de Vigilância Sanitária & Fiocruz, Rio de Janeiro 21041-361, Brazil
3
Centro de Transplante de Medula Óssea Laboratório de Oncovirologia, Instituto Nacional do Câncer, Rio de Janeiro 20230-130, Brazil
4
Laboratório de Bioquímica e Proteínas de Peptídeos, CDTS Centro de Desenvolvimento Tecnológico em Saúde, Fiocruz, Rio de Janeiro 21041-361, Brazil
5
Núcleo de Controle da Malária/Departamento de Vigilância Epidemiológica/Coordenação Geral de Vigilância em Saúde/SESAU-RR, Boa Vista 69305-080, Brazil
6
Fundação Instituto de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Amazonas 69040-000, Brazil
7
Centro de Pesquisa em Doenças Infecciosas, Universidade Federal do Acre, Rio Branco 69920-900, Brazil
8
Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro 21040-361, Brazil
*
Author to whom correspondence should be addressed.
Pathogens 2023, 12(5), 731; https://doi.org/10.3390/pathogens12050731
Submission received: 26 March 2023 / Revised: 10 May 2023 / Accepted: 12 May 2023 / Published: 17 May 2023
(This article belongs to the Special Issue Parasites: Epidemiology, Treatment and Control)

Abstract

:
(1) Background: Malaria is a public health problem worldwide. Despite global efforts to control it, antimalarial drug resistance remains a great challenge. In 2009, our team identified, for the first time in Brazil, chloroquine (CQ)-susceptible Plasmodium falciparum parasites in isolates from the Brazilian Amazon. The present study extends those observations to include survey samples from 2010 to 2018 from the Amazonas and Acre states for the purpose of tracking pfcrt molecular changes in P. falciparum parasites. (2) Objective: to investigate SNPs in the P. falciparum gene associated with chemoresistance to CQ (pfcrt). (3) Methods: Sixty-six P. falciparum samples from the Amazonas and Acre states were collected from 2010 to 2018 in patients diagnosed at the Reference Research Center for Treatment and Diagnosis of Malaria (CPD-Mal/Fiocruz), FMT-HVD and Acre Health Units. These samples were subjected to PCR and DNA Sanger sequencing to identify mutations in pfcrt (C72S, M74I, N75E, and K76T). (4) Results: Of the 66 P. falciparum samples genotyped for pfcrt, 94% carried CQ-resistant genotypes and only 4 showed a CQ pfcrt sensitive-wild type genotype, i.e., 1 from Barcelos and 3 from Manaus. (5) Conclusion: CQ-resistant P. falciparum populations are fixed, and thus, CQ cannot be reintroduced in malaria falciparum therapy.

1. Introduction

Tens of thousands of years after the Plasmodia that infected hominids became established as parasites that cause disease in humans, malaria is still a major public health problem worldwide in the third millennium of the Christian era. According to the World Malaria Report, 247 million cases and 619 thousand malaria-related deaths were reported in 2021 [1]. Plasmodium falciparum is responsible for the most virulent and dangerous malaria in humans [1,2]. In 2021, in the Brazilian Amazon Basin, 138,988 cases—representing 99.92% of the Brazilian cases—were reported. Among them, 21,614 (15.55%) were caused by P. falciparum [2].
Despite numerous advances in the use and efficacy of vaccines, there is still heavy reliance on antimalarials for the prevention and treatment of malaria; these drugs are considered the most important malaria control measures [3]. However, with the continued use of antimalarials, P. falciparum gradually develops drug resistance that spreads rapidly [4]. Therefore, antimalarial drug resistance has become one of the major challenges in eliminating the disease [5]. The emergence of drug-resistant strains may be influenced by parasites and host factors, such as parasite mutation frequency, patient adherence to therapy, selection pressure, and host immunity, in addition to drug quality [6].
Before artemisinin-based combination therapies (ACTs) were approved worldwide as first-line therapy for uncomplicated falciparum malaria in 2007, chloroquine (CQ) was widely used in Brazil, especially up to the 1980s, to treat acute infections with P. falciparum as a safe, inexpensive, and effective antimalarial drug [7,8,9]. Mefloquine was then introduced as a therapeutic alternative for multidrug-resistant falciparum malaria; it was used until the introduction of ACTs in Brazil, with relative safety, alone or in association with artemisinin derivatives in cases of severe malaria and multidrug-resistant P. falciparum parasites [10]. Currently, after reports of cases of resistance to mefloquine [10], this drug is only used in combination with artesunate for the treatment of acute, uncomplicated malaria caused by P. falciparum. It is indicated for cases of P. falciparum mono-infection, as well as for mixed infections with P. vivax (with subsequent treatment of its hypnozoite forms).
Since the first reports of P. falciparum resistance to antimalarial drugs in the nineteenth century, molecular epidemiological surveillance has been essential for the early detection and prevention of the spread of resistant parasites [11,12] by identifying and monitoring genetic polymorphisms associated with parasite resistance, mainly single nucleotide polymorphisms (SNPs) [8,12].
Mutations in the P. falciparum chloroquine resistance transporter gene (pfcrt), a member of the drug metabolite transporter superfamily, have been associated with reduced susceptibility to CQ [11]. The K76T pfcrt polymorphism is considered the molecular marker of CQ resistance (CQR) [13] and is associated with CQ treatment failure [14,15]. However, studies have suggested that the K76T mutation does not act alone but in conjunction with other pfcrt mutations, such as those at positions 72, 73, 74, and 75 [16,17,18]. Thus, CQR strains of P. falciparum could carry triple CVIET (mostly in Southeast Asia and Africa) or double SVMNT mutants (South America) [19,20,21,22].
In 2009, our team identified, for the first time in Brazil, the presence of P. falciparum parasites sensitive to CQ in the Brazilian Amazon [23]. The present study extends these observations to include survey samples from 2010 to 2018 from the Amazonas and Acre. Due to the limitations of in vivo and in vitro studies to survey chemoresistant parasites in endemic areas where reinfections are common, molecular analysis of parasite mutations associated with chemoresistance is an important tool. These findings prompted us to conduct a study to track molecular changes in P. falciparum parasites through the investigation of SNPs in the pfcrt gene in parasites from the Amazonas and Acre Brazilian states.

2. Materials and Methods

2.1. Blood Samples and Malaria Diagnosis

Samples were collected from P. falciparum-infected symptomatic patients who attended the Ambulatório de Síndromes Febris Agudas/Acute Febrile Syndrome Outpatient Clinic at the National Institute of Infectology (INI), Rio de Janeiro, a member of the Reference Center for Research, Diagnosis, and Training of Malaria—CPD-Mal/Fiocruz, RJ for the Extra-Amazonian region (22° 54′ S W 43° 12′ W). Blood samples were also collected in Manaus (3.1190° S, 60.0217° W), the capital of Amazon state, at the Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD) and in field conditions in the municipality of Guajará (bordering the Amazonas and Acre states; 02°58′18′′ S and 57°40′38′′ W) and in two municipalities of Acre state: Cruzeiro do Sul (07°37′50′′ S and 72°40′13′′ W) and Mâncio Lima (07°36′49′′ S and 72°53′47′′ W) (Table 1 and Figure 1). Independently of blood collection locality, P. falciparum diagnosis was made by light microscopy (Giemsa-stained thick blood droplets) in situ and by species-specific polymerase chain reaction (PCR) [24] at the Fiocruz Malaria Research Laboratory—the headquarters of the CPD-Mal—where the samples were stored.

2.2. DNA Extraction, Amplification, and Sequencing

The DNA from 1 mL blood samples was extracted using a QIAamp™ DNA Blood Midi Kit (QIAGEN), according to the manufacturer’s instructions. PCRs were performed to amplify the pfcrt fragment gene according to previously described protocols [25]. PCR products were analyzed by electrophoresis on 2% agarose gel and visualized under a UV transilluminator (DigiDoc-It, UVP, Upland, CA, USA). Each PCR product was purified using Wizard™ SV Gel and the PCR Clean-Up System (Promega, WI, USA), following the manufacturer’s procedure. Purified DNA sequencing was carried out through Big Dye™ Terminator Cycle Sequencing Ready Reaction version 3.1 (Applied Biosystems, Carlsbad, CA, USA), with 3.2 μM of forward and reverse PCR primers. DNA sequences to investigate C72S, M74I, N75E/D, and K76T were determined using an ABI Prism DNA Analyzer™ 3730 (Applied Biosystems, CA, USA), on the Fiocruz Genomic Platform PDTIS/Fiocruz RPT01A. Nucleotide sequences were aligned using the ClustalW multiple sequence aligner in the BioEdit software [26]. The PF3D7_1343700 strain was used as a reference sequence (from PlasmoDB: http://www.plasmoDB.org, accessed on 20 March 2023). DNA sequences were deposited in GenBank (the NIH’s genetic sequence database; www.ncbi/nlm/nih.gov/GenBank, accessed on 21 March 2023) with the accession numbers OQ672386-OQ672451.

3. Results

PCR amplicons (145-bp) of the pfcrt gene covering codons 72–76 were sequenced. The prevalence of C72S and K76T mutations was 92% (61/66). All parasites from Cruzeiro do Sul and Mâncio Lima Acre municipalities, as well as those from Guajará Amazonas municipality, showed both C72S and K76T polymorphisms, i.e., exhibiting the double mutant SVMNT haplotype. Only four samples from Amazonas municipalities—three from Manaus and one from Barcelos—were pfcrt CVMNK wild type. The remaining sample from Manaus presented mutations at codons 74 (M74I), 75 (N75E), and 76 (K76T), displaying the triple mutant CVIET haplotype (Table 2).

4. Discussion

The P. falciparum has demonstrated its ability to develop resistance to all drugs that have been used against it on a large scale, continuously threatening global efforts to control malaria, a leading infectious cause of human morbidity and mortality. Although Africa bears by far the heaviest burden of malaria, CQ-resistant parasites first emerged in Southeast Asia and America [27]. This fact underscores the importance of studying and understanding the genotype of circulating parasites in malaria-endemic areas, since the strong pressure of drugs can lead to the establishment of drug resistance alleles, even if they generate a fitness cost for parasites in the absence of drug pressure [28]. Therefore, understanding the evolution of drug target genes under changing drug policy is crucial for drug efficacy monitoring using molecular markers.
Polymorphisms in the amino acid positions 72–76 of the pfcrt gene are reliable markers for CQR of P. falciparum parasites, of which K76T mutation is predominant [16,29]. In our study, the high prevalence of the 76T allele in isolates from Acre and Amazonas agrees with other studies in Brazil [30,31], and 76T mutation was found in two CQR haplotypes, CVIET and SVMNT, which was consistent with our initial hypothesis.
The CVIET haplotype is predominant in many African [21,32] and Southeast Asian countries in which CQ has been withdrawn for at least ten years after [33,34,35]; however, it has also been observed in P. falciparum parasites from South America [36], while SVMNT is dominant in South America and Oceania [37]. In Brazil, the CVIET haplotype was rarely encountered (it was found in only one sample from the municipality of Manaus), as previously seen in isolates from Amazonas and Rondônia [38]. This low CVIET haplotype frequency in Brazilian isolates suggests that this allele might have been recently introduced through human migration between Africa and South America.
On the other hand, the SVMNT haplotype is mainly detected in South America and is rarely found in Africa [21,39] and Southeast Asia [33,34,35]. A study released in 2022 claimed that the SVMNT haplotype originated independently in South America [22], and it was suggested that this haplotype might be responsible for the initial CQR sweeps across the Amazon in the early 1960s [38]. SVMNT was more prevalent than other mutant haplotypes found in this survey, corroborating previous findings in Brazil [24] and showing its persistence, despite a decline in CQ use.
Our team reported, for the first time, the presence of wild-type haplotypes circulating in Brazilian isolates [23]. Now, almost ten years later, we found this haplotype in only four isolates from the Amazonas state (three from Manaus and one from Barcelos). Considering that in Brazil, CQ has not been used to treat P. falciparum since the 1980s, a higher percentage of parasites sensitive to CQ would theoretically be expected. In fact, up to 90% of the samples showing a reversal of pfcrt from the CQ-resistant to the CQ-sensitive genotype were taken 19 years after the withdrawal of CQ in Kenya, in contrast to the results observed in the present study [40]. Thus, the high level of K76T pfcrt mutations observed in Brazilian endemic areas is suggestive of a sustained CQ pressure on P. falciparum parasites. In fact, CQ is used in the treatment of vivax malaria, leading to continuous exposure to this drug. Alternatively, the presence of a K76T mutation might have a positive effect on the fitness of the parasite, settling down in the parasitic population of the region, or lesser opportunities for competition because of a lower rate of polyclonal infections and a relative lack of competing wild-type parasites [41] Additionally, C350R substitution on the pfcrt gene could also participate in the restoration of CQ susceptibility, as suggested elsewhere [28]. Since the C350R mutation is in exon 10, and the primers we used flank the exon 2 region, comprising amino acids located at codons 43-91, studies are in progress to answer this question.

5. Conclusions

We conclude that the P. falciparum SVMNT haplotype is fixed in Brazilian endemic areas. This notwithstanding, molecular surveillance of the P. falciparum pfcrt gene to monitor trends in the emergence and spread of CQ-sensitive P. falciparum haplotypes in parasites in Brazilian endemic areas can help to understand the evolutionary dynamics of antimalarial drug resistance in the Amazon Basin, where more than 99% of Brazilian malaria cases occur and where P. falciparum resistance to CQ keeps being the rule.

Author Contributions

Conceptualization: M.d.F.F.-d.-C.; supervision: M.d.F.F.-d.-C.; methodology: R.d.A.-F., B.E.G., L.T.d.Q., A.R.D.L.M. and L.R.G.; epidemiological survey: M.d.G.C.A., R.M.d.S., L.R.P.-R. and P.B.; formal analysis: R.d.A.-F., N.K.A.-d.-O., L.T.d.Q., J.d.A.B. and M.d.F.F.-d.-C.; investigation: M.d.F.F.-d.-C. and C.T.D.-R.; resources: M.d.F.F.-d.-C.; original draft preparation: R.d.A.-F.; writing—review: M.d.F.F.-d.-C. and C.T.D.-R.; editing: R.d.A.-F., N.K.A.-d.-O.; project administration: M.d.F.F.-d.-C.; funding acquisition: M.d.F.F.-d.-C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; http://www.cnpq.br/, accessed on 10 March 2022) through a Research Productivity Fellowships to C.T.D.-R. (310445/2017-5), M.d.F.F.-d.-C. (306025/2018-3) and P.B. (311562/2021-3) that are also Cientistas do Nosso Estado (C.T.D.-R.—E-26/202.921/2018; M.d.F.F.-d.-C.—E-26/203.295/2015 and P.B. (E-26/200.925/2022) of the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado de Rio de Janeiro (FAPERJ; http://www.faperj.br/, accessed on 10 March 2022). This work was also supported by Departamento de Ciência e Tecnologia em Saúde/Ministério da Saúde (DECIT/MS) (Grant Number: 402675/2018-5), Programa Nacional de Controle e Prevenção da Malária/Secretaria de Vigilância em Saúde/Ministério da Saúde (SVS/MS) and Fiocruz (Grant Number: 026-FIO-18-2-1).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Ethical approval for the study was obtained from the Ethics and Research Committee of Research in Human Beings at Fiocruz under the number 221/03 and CAAE 88554718.0.3002.5248 to Amazonas samples and CAAE 46084015.1.0000.5248 to Acre samples.

Data Availability Statement

Data supporting the conclusions of this article are included within the article. The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Acknowledgments

We would like to thank all the patients for their participation in this study. We would also to acknowledge the staffs from the Genomic Platform for DNA sequencing facilities RPT01A/PDTIS/Fiocruz and the Coordenação de Vigilância em Saúde e Laboratórios de Referência, Fiocruz/Coordination of Health Surveillance and Reference Laboratories for financial and logistical support. All authors have approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. World Health Organization. World Malaria Report 2022; World Health Organization: Geneva, Switzerland, 2022; pp. 1–293. ISBN 9789240064898. Available online: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022 (accessed on 5 March 2023).
  2. Tableau Public. Malaria 2022. Available online: https://public.tableau.com/app/profile/mal.ria.brasil/viz/Dadosparacidado_201925_03_2020/Incio (accessed on 5 March 2023).
  3. Wicht, K.J.; Mok, S.; Fidock, D.A. Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria. Annu. Rev. Microbiol. 2020, 74, 431–454. [Google Scholar] [CrossRef]
  4. Goswami, D.; Dhiman, S.; Rabha, B.; Kumar, D.; Baruah, I.; Sharma, D.K.; Veer, V. Pfcrt mutant haplotypes may not correspond with chloroquine resistance. J. Infect. Dev. Ctries. 2014, 8, 768–773. [Google Scholar] [CrossRef] [PubMed]
  5. Mathieu, L.C.; Cox, H.; Early, A.M.; Mok, S.; Lazrek, Y.; Paquet, J.C.; Ade, M.P.; Lucchi, N.W.; Grant, Q.; Udhayakumar, V.; et al. Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance. Elife 2020, 9, e51015. [Google Scholar] [CrossRef] [PubMed]
  6. Yan, H.; Feng, J.; Yin, J.H.; Huang, F.; Kong, X.L.; Lin, K.M.; Zhang, T.; Feng, X.Y.; Zhou, S.S.; Cao, J.P.; et al. High-Frequency Mutations in pfdhfr and pfdhps of Plasmodium falciparum in Response to Sulfadoxine-Pyrimethamine: A Cross-Sectional Survey in Returning Chinese Migrants from Africa. Front. Cell. Infect. Microbiol. 2021, 11, 673194. [Google Scholar] [CrossRef] [PubMed]
  7. Haldar, K.; Bhattacharjee, S.; Safeukui, I. Drug resistance in Plasmodium. Nat. Rev. Microbiol. 2018, 16, 156–170. [Google Scholar] [CrossRef] [PubMed]
  8. Gama, B.E.; Lacerda, M.V.; Daniel-Ribeiro, C.T.; de Ferreira-da-Cruz, M.F. Chemoresistance of Plasmodium falciparum and Plasmodium vivax parasites in Brazil: Consequences on disease morbidity and control. Mem. Inst. Oswaldo. Cruz. 2011, 106, 159–166. [Google Scholar] [CrossRef]
  9. Valenzuela, G.; Castro, L.E.; Valencia-Zamora, J.; Vera-Arias, C.A.; Rohrbach, P.; Sáenz, F.E. Genotypes and phenotypes of resistance in Ecuadorian Plasmodium falciparum. Malar. J. 2019, 18, 415. [Google Scholar] [CrossRef] [PubMed]
  10. Noronha, E.; das Alecrim, M.G.; Romero, G.A.S.; Macêdo, V. Resistência à mefloquina do tipo RIII em crianças com malária falciparum em Manaus, AM, Brasil. Rev. Soc. Bras. Med. Trop. 2000, 33, 201–205. [Google Scholar] [CrossRef]
  11. Costa, G.L.; Amaral, L.C.; Fontes, C.J.F.; Carvalho, L.H.; de Brito, C.F.A.; de Sousa, T.N. Assessment of copy number variation in genes related to drug resistance in Plasmodium vivax and Plasmodium falciparum isolates from the Brazilian Amazon and a systematic review of the literature. Malar. J. 2017, 16, 152. [Google Scholar] [CrossRef]
  12. Mvumbi, D.M.; Kayembe, J.M.; Situakibanza, H.; Bobanga, T.L.; Nsibu, C.N.; Mvumbi, G.L.; Melin, P.; De Mol, P.; Hayette, M.P. Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: A systematic review. Malar. J. 2015, 14, 354. [Google Scholar] [CrossRef]
  13. Fidock, D.A.; Nomura, T.; Talley, A.K.; Cooper, R.A.; Dzekunov, S.M.; Ferdig, M.T.; Ursos, L.M.; Sidhu, A.B.; Naudé, B.; Deitsch, K.W.; et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell. 2000, 6, 861–871. [Google Scholar] [CrossRef]
  14. Zhao, Y.; Liu, Z.; Soe, M.T.; Wang, L.; Soe, T.N.; Wei, H.; Than, A.; Aung, P.L.; Li, Y.; Zhang, X.; et al. Genetic Variations Associated with Drug Resistance Markers in Asymptomatic Plasmodium falciparum Infections in Myanmar. Genes 2019, 10, 692. [Google Scholar] [CrossRef]
  15. Djimdé, A.; Doumbo, O.K.; Cortese, J.F.; Kayentao, K.; Doumbo, S.; Diourté, Y.; Coulibaly, D.; Dicko, A.; Su, X.Z.; Nomura, T.; et al. A molecular marker for chloroquine resistant falciparum malaria. N. Engl. J. Med. 2001, 344, 257–263. [Google Scholar] [CrossRef]
  16. Ibrahim, M.L.; Steenkeste, N.; Khim, N.; Adam, H.H.; Konaté, L.; Coppée, J.Y.; Ariey, F.; Duchemin, J.B. Field-based evidence of fast and global increase of Plasmodium falciparum drug resistance by DNA-microarrays and PCR/RFLP in Niger. Malar. J. 2009, 8, 32. [Google Scholar] [CrossRef]
  17. Awasthi, G.; Satya Prasad, G.B.; Das, A. Pfcrt haplotypes and the evolutionary history of chloroquine-resistant Plasmodium falciparum. Memórias Inst. Oswaldo Cruz. 2012, 107, 129–134. [Google Scholar] [CrossRef]
  18. Gresty, K.J.; Gray, K.A.; Bobogare, A.; Taleo, G.; Hii, J.; Wini, L.; Cheng, Q.; Waters, N.C. Genetic mutations in pfcrt and pfmdr1 at the time of artemisinin combination therapy introduction in South Pacific islands of Vanuatu and Solomon Islands. Malar J. 2014, 13, 406. [Google Scholar] [CrossRef] [PubMed]
  19. Gama, B.E.; Pereira-Carvalho, G.A.; Lutucuta Kosi, F.J.; Almeida de Oliveira, N.K.; Fortes, F.; Rosenthal, P.J.; Daniel-Ribeiro, C.T.; de Fátima Ferreira-da-Cruz, M. Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene. Malar. J. 2010, 9, 174. [Google Scholar] [CrossRef] [PubMed]
  20. Hassen, J.; Alemayehu, G.S.; Dinka, H.; Golassa, L. High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia. Malar. J. 2022, 21, 286. [Google Scholar] [CrossRef]
  21. Mehlotra, R.K.; Mattera, G.; Bockarie, M.J.; Maguire, J.D.; Baird, J.K.; Sharma, Y.D.; Alifrangis, M.; Dorsey, G.; Rosenthal, P.J.; Fryauff, D.J.; et al. Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite P. falciparum. Antimicrob. Agents Chemother. 2008, 52, 2212–2222. [Google Scholar] [CrossRef] [PubMed]
  22. Wootton, J.C.; Feng, X.; Ferdig, M.T.; Cooper, R.A.; Mu, J.; Baruch, D.I.; Magill, A.J.; Su, X.Z. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 418, 320–323. [Google Scholar] [CrossRef] [PubMed]
  23. Gama, B.E.; de Oliveira, N.K.; Zalis, M.G.; de Souza, J.M.; Santos, F.; Daniel-Ribeiro, C.T.; de Ferreira-da-Cruz, M.F. Chloroquine and sulphadoxine-pyrimethamine sensitivity of Plasmodium falciparum parasites in a Brazilian endemic area. Malar. J. 2009, 8, 156. [Google Scholar] [CrossRef] [PubMed]
  24. Zalis, M.G.; Ferreira-da-Cruz, M.F.; Balthazar-Guedes, H.C.; Banic, D.M.; Alecrim, W.; Souza, J.M.; Druilhe, P.; Daniel-Ribeiro, C.T. Malaria diagnosis: Standardization of a polymerase chain reaction for the detection of Plasmodium falciparum parasites in individuals with low-grade parasitemia. Parasitol. Res. 1996, 82, 612–616. [Google Scholar] [CrossRef] [PubMed]
  25. Zhou, R.M.; Zhang, H.W.; Yang, C.Y.; Liu, Y.; Zhao, Y.L.; Li, S.H.; Qian, D.; Xu, B.L. Molecular mutation profile of pfcrt in Plasmodium falciparum isolates imported from Africa in Henan province. Malar. J. 2016, 15, 265. [Google Scholar] [CrossRef]
  26. Hall, T.A. BioEdit: A User-Friendly Biological Sequence Alignment Editor and Analysis Program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 1999, 41, 95–98. [Google Scholar]
  27. Naidoo, I.; Roper, C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria. Trends Parasitol. 2013, 29, 505–515. [Google Scholar] [CrossRef]
  28. Pelleau, S.; Moss, E.L.; Dhingra, S.K.; Volney, B.; Casteras, J.; Gabryszewski, S.J.; Volkman, S.K.; Wirth, D.F.; Legrand, E.; Fidock, D.A.; et al. Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proc. Natl. Acad. Sci. USA 2015, 112, 11672–11677. [Google Scholar] [CrossRef]
  29. Mulenga, M.C.; Sitali, L.; Ciubotariu, I.I.; Hawela, M.B.; Hamainza, B.; Chipeta, J.; Mharakurwa, S. Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia. Malar. J. 2021, 20, 329. [Google Scholar] [CrossRef]
  30. Inoue, J.; Lopes, D.; do Rosário, V.; Machado, M.; Hristov, A.D.; Lima, G.F.; Costa-Nascimento, M.J.; Segurado, A.C.; Di Santi, S.M. Analysis of polymorphisms in Plasmodium falciparum genes related to drug resistance: A survey over four decades under different treatment policies in Brazil. Malar. J. 2014, 13, 372. [Google Scholar] [CrossRef]
  31. Aguiar, A.C.; Pereira, D.B.; Amaral, N.S.; De Marco, L.; Krettli, A.U. Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondonia, West Amazon, Brazil. Malar. J. 2014, 13, 73. [Google Scholar] [CrossRef]
  32. Gama, B.E.; de Oliveira, N.K.; de Souza, J.M.; Santos, F.; de Carvalho, L.J.; Melo, Y.F.; Rosenthal, P.J.; Daniel-Ribeiro, C.T.; de Ferreira-da-Cruz, M.F. Brazilian P. falciparum isolates investigation of candidate polymorphisms for artemisinin resistance before the introduction of artemisinin-based combination therapy. Malar. J. 2010, 9, 355. [Google Scholar] [CrossRef] [PubMed]
  33. Boonyalai, N.; Thamnurak, C.; Sai-Ngam, P.; Ta-Aksorn, W.; Arsanok, M.; Uthaimongkol, N.; Sundrakes, S.; Chattrakarn, S.; Chaisatit, C.; Praditpol, C.; et al. Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand. Sci. Rep. 2021, 11, 13419. [Google Scholar] [CrossRef]
  34. Srimuang, K.; Miotto, O.; Lim, P.; Fairhurst, R.M.; Kwiatkowski, D.P.; Woodrow, C.J.; Imwong, M. Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration. Malar. J. 2016, 15, 541. [Google Scholar] [CrossRef] [PubMed]
  35. Imwong, M.; Dhorda, M.; Tun, K.M.; Thu, A.M.; Phyo, A.P.; Proux, S.; Suwannasin, K.; Kunasol, C.; Srisutham, S.; Duanguppama, J.; et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: An observational study. Lancet. Infect. Dis. 2020, 20, 1470–1480. [Google Scholar] [CrossRef] [PubMed]
  36. Cortese, J.F.; Caraballo, A.; Contreras, C.E.; Plowe, C.V. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J. Infect. Dis. 2002, 186, 999–1006. [Google Scholar] [CrossRef] [PubMed]
  37. Hussien, M.; Abdel Hamid, M.M.; Elamin, E.A.; Hassan, A.O.; Elaagip, A.H.; Salama, A.H.A.; Abdelraheem, M.H.; Mohamed, A.O. Antimalarial drug resistance molecular makers of Plasmodium falciparum isolates from Sudan during 2015–2017. PLoS ONE 2021, 15, e0235401. [Google Scholar] [CrossRef]
  38. Vieira, P.P.; Ferreira, M.U.; Alecrim, M.d; Alecrim, W.D.; da Silva, L.H.; Sihuincha, M.M.; Joy, D.A.; Mu, J.; Su, X.Z.; Zalis, M.G. pfcrt Polymorphism and the spread of chloroquine resistance in Plasmodium falciparum populations across the Amazon Basin. J. Infect. Dis. 2004, 190, 417–424. [Google Scholar] [CrossRef] [PubMed]
  39. Awasthi, G.; Das, A. Genetics of chloroquine-resistant malaria: A haplotypic view. Mem. Inst. Oswaldo. Cruz. 2013, 108, 947–961. [Google Scholar] [CrossRef]
  40. Zhou, Z.; Gimnig, J.E.; Sergent, S.B.; Liu, Y.; Abong’o, B.; Otieno, K.; Chebore, W.; Shah, M.P.; Williamson, J.; Ter Kuile, F.O.; et al. Temporal trends in molecular markers of drug resistance in Plasmodium falciparum in human blood and profiles of corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. Malar. J. 2022, 21, 265. [Google Scholar] [CrossRef] [PubMed]
  41. Ecker, A.; Lehane, A.M.; Clain, J.; Fidock, D.A. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 2012, 28, 504–514. [Google Scholar] [CrossRef]
Figure 1. Brazilian map highlighting the Acre and Amazonas states and the municipalities of parasite infection.
Figure 1. Brazilian map highlighting the Acre and Amazonas states and the municipalities of parasite infection.
Pathogens 12 00731 g001
Table 1. Localities of P. falciparum parasite blood collection by year.
Table 1. Localities of P. falciparum parasite blood collection by year.
YearSample Collection
Rio de Janeiro (n = 2)Amazonas (n = 32)Acre (n = 34)
CPDMAL 1FMT-HVD 2GJ 3CZS 4ML 5
2010-22---
2013-4---
2014-1---
2016--1118
20171 6----
20181 7-296
1 Reference Center for Malaria Treatment and Diagnosis of Brazilian Ministry of Health. 2 Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Amazonas state. 3 Guajará municipality, Amazonas state; 4 Cruzeiro do Sul municipality, Acre state; 5 Mâncio Lima municipality, Acre state; 6 Manaus municipality, Amazonas state; 7 Barcelos municipality, Amazonas state.
Table 2. pfcrt haplotypes in 66 P. falciparum samples from Amazonas (Manaus, Barcelos, and Guajará/GJ) and Acre (Cruzeiro do Sul/CZS and Mâncio Lima/ML) Brazilian states.
Table 2. pfcrt haplotypes in 66 P. falciparum samples from Amazonas (Manaus, Barcelos, and Guajará/GJ) and Acre (Cruzeiro do Sul/CZS and Mâncio Lima/ML) Brazilian states.
Haplotype 1LocalityTotal (%)
Manaus
(n = 28)
Barcelos
(n = 1)
GJ
(n = 3)
CZS
(n = 20)
ML
(n = 14)
CVMNK 23 (11%)1 (100%)---4 (6%)
SVMNT324 (86%)-3 (100%)20 (100%)14 (100%)61 (92%)
CVIET 41 (4%)----1 (1%)
1 The bold character represents a non-synonymous mutation. 2 Reference Pf3D7 wild haplotype sequence. 3 S: codon 72; T: codon 76. 4 I: codon 74; E: codon 75; T: codon 76.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

de Abreu-Fernandes, R.; Almeida-de-Oliveira, N.K.; Gama, B.E.; Gomes, L.R.; De Lavigne Mello, A.R.; Queiroz, L.T.d.; Barros, J.d.A.; Alecrim, M.d.G.C.; Medeiros de Souza, R.; Pratt-Riccio, L.R.; et al. Plasmodium falciparum Chloroquine-pfcrt Resistant Haplotypes in Brazilian Endemic Areas Four Decades after CQ Withdrawn. Pathogens 2023, 12, 731. https://doi.org/10.3390/pathogens12050731

AMA Style

de Abreu-Fernandes R, Almeida-de-Oliveira NK, Gama BE, Gomes LR, De Lavigne Mello AR, Queiroz LTd, Barros JdA, Alecrim MdGC, Medeiros de Souza R, Pratt-Riccio LR, et al. Plasmodium falciparum Chloroquine-pfcrt Resistant Haplotypes in Brazilian Endemic Areas Four Decades after CQ Withdrawn. Pathogens. 2023; 12(5):731. https://doi.org/10.3390/pathogens12050731

Chicago/Turabian Style

de Abreu-Fernandes, Rebecca, Natália Ketrin Almeida-de-Oliveira, Bianca Ervatti Gama, Larissa Rodrigues Gomes, Aline Rosa De Lavigne Mello, Lucas Tavares de Queiroz, Jacqueline de Aguiar Barros, Maria das Graças Costa Alecrim, Rodrigo Medeiros de Souza, Lilian Rose Pratt-Riccio, and et al. 2023. "Plasmodium falciparum Chloroquine-pfcrt Resistant Haplotypes in Brazilian Endemic Areas Four Decades after CQ Withdrawn" Pathogens 12, no. 5: 731. https://doi.org/10.3390/pathogens12050731

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop